文献速递肝胆胰外科胃肠外科围术期管理与 ERAS

新辅助化疗对结直肠癌肝转移肝切除术后结局的影响:基于人群的倾向性匹配分析

Impact of Neoadjuvant Chemotherapy on the Postoperative Outcomes of Patients Undergoing Liver Resection for Colorectal Liver Metastases: A Population-Based Propensity-Matched Analysis.
PubMed 文献 · J Am Coll Surg · 2019-03-22

该研究利用美国外科医师学会NSQIP靶向肝切除数据库2014至2016年数据,经倾向性评分匹配后纳入1416对接受与未接受新辅助化疗的结直肠癌肝转移肝切除患者。结果显示两组30天总体并发症、胆瘘、肝切除后肝衰竭及死亡率均无差异,多因素分析中新辅助化疗与并发症或死亡风险增加无关。

要点

  • 新辅助化疗未增加结直肠癌肝转移肝切除术后30天并发症率(34% vs 33%)。
  • 胆瘘(6% vs 5%)、肝切除后肝衰竭(5% vs 5%)及死亡率(0.8% vs 0.7%)两组相似。
  • 多因素分析显示新辅助化疗与并发症(OR 1.07)或死亡(OR 1.09)风险增加无关。

核心结论

  • 在倾向性匹配的基于人群队列中,新辅助全身化疗与结直肠癌肝转移肝切除患者更高的并发症、胆瘘、肝切除后肝衰竭或死亡率无关。

研究设计与样本

  • 基于美国外科医师学会NSQIP靶向肝切除参与使用文件2014至2016年数据的回顾性队列研究,采用倾向性评分匹配比较接受与未接受新辅助化疗的结直肠癌肝转移肝切除患者。
  • 匹配后新辅助化疗组与未接受新辅助化疗组各1416例(各占50%)。

主要发现

  • 匹配后两组年龄(60岁 vs 61岁)、最大肿瘤大小(≤5 cm:79% vs 80%;>5 cm:21% vs 20%)、切除类型(部分肝切除:69% vs 70%)、同期结肠切除(9% vs 9%)及术前门静脉栓塞(5% vs 5%)均无差异(均p>0.05)。
  • 30天总体术后并发症(34% vs 33%)、胆瘘(6% vs 5%)、肝切除后肝衰竭(5% vs 5%)及死亡率(0.8% vs 0.7%)在新辅助化疗组与未接受组间相似(均p>0.05)。
  • 多因素分析中,接受新辅助化疗与并发症增加无关(OR 1.07;95%CI 0.90至1.27;p=0.43),与死亡增加也无关(OR 1.09;95%CI 0.44至2.72;p=0.85)。

临床怎么用

  • 对于结直肠癌肝转移拟行肝切除的患者,新辅助全身化疗未显示增加术后30天并发症、胆瘘、肝切除后肝衰竭或死亡风险,围术期决策时可参考该安全性证据。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of neoadjuvant chemotherapy in the management of colorectal liver metastases remains controversial. We sought to investigate whether neoadjuvant systemic chemotherapy contributes to clinically significant increases in postoperative morbidity and mortality using a population-based cohort. STUDY DESIGN: The American College of Surgeons NSQIP Targeted Hepatectomy Participant Use Files were queried from 2014 to 2016 to identify patients with colorectal liver metastases who underwent liver resection. Patients were stratified by receipt of neoadjuvant chemotherapy using propensity score matching. Univariate and multivariable analyses were used to characterize the effect of neoadjuvant chemotherapy on perioperative morbidity and mortality. RESULTS: After propensity score matching, 1,416 (50%) patients received neoadjuvant chemotherapy before hepatectomy and 1,416 (50%) underwent liver resection without neoadjuvant chemotherapy. There were no differences in age (60 vs 61 years), maximum tumor size (≤5 cm: 79% vs 80%, >5 cm: 21% vs 20%), resection type (partial hepatectomy: 69% vs 70%), simultaneous colectomy (9% vs 9%), or use of preoperative portal vein embolization (5% vs 5%) in those undergoing neoadjuvant chemotherapy compared with those who did not (all, p > 0.05). Overall 30-day postoperative morbidity (34% vs 33%), including rates of biliary fistula (6% vs 5%), post-hepatectomy liver failure (5% vs 5%), and mortality rates (0.8% vs 0.7%), were similar among patients who received neoadjuvant chemotherapy vs those who did not (all, p > 0.05). On multivariable analysis, receipt of neoadjuvant chemotherapy was not associated with increased morbidity (odds ratio 1.07; 95% CI 0.90 to 1.27; p = 0.43) or mortality (odds ratio 1.09; 95% CI 0.44 to 2.72; p = 0.85). CONCLUSIONS: In this propensity-matched population-based cohort study, the use of neoadjuvant systemic chemotherapy was not associated with higher rates of complications, biliary fistula, post-hepatectomy liver failure, or mortality among patients with colorectal liver metastases undergoing liver resection.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Wiseman JT, Guzman-Pruneda F, Xourafas D, et al. Impact of Neoadjuvant Chemotherapy on the Postoperative Outcomes of Patients Undergoing Liver Resection for Colorectal Liver Metastases: A Population-Based Propensity-Matched Analysis. J Am Coll Surg. 2019. PMID: 30905856. doi:10.1016/j.jamcollsurg.2019.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。